Abdullah Hamadeh, Director

Abdullah Hamadeh received his PhD in control systems engineering from the University of Cambridge and conducted postdoctoral work in systems and synthetic biology at MIT. His main research interests include the development of optimization algorithms for complex systems, with applications in pharmacokinetic modeling, systems pharmacology, and epidemiology.   He specializes in the development of computational tools for robust PBPK in vitro-in vivo extrapolation, virtual bioequivalence assessment and global sensitivity analysis.   He is also an active contributor to the development of the Open Systems Pharmacology Suite.  

Publications

PBPK modeling

• Abdullah Hamadeh, John Troutman, Andrea Edginton. Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models. Pharmaceutics, 2021, 13(6), 807.  https://doi.org/10.3390/pharmaceutics13060807
  
  

• Esther Yun, Daniella Calderon-Nieva, Abdullah Hamadeh, Andrea Edginton. Development and Evaluation of an In Silico Dermal Absorption Model Relevant for Children. Pharmaceutics 2022, 14(1), 172.  https://doi.org/10.3390/pharmaceutics14010172
  
  

• Abdullah Hamadeh, John Troutman, Abdulkarim Najjar, Andrea Edginton.  A Mechanistic Bayesian Inferential Workflow for Estimation of In Vivo Skin Permeation from In Vitro Measurements.  Journal of Pharmaceutical Sciences, 2022, 111(3), 838-851. https://doi.org/10.1016/j.xphs.2021.11.028
  
  

• Abdullah Hamadeh, Andrea Edginton.  Efficient large-scale mechanism-based computation of skin permeability. Computational Toxicology, 2023.
  
  

• Abdullah Hamadeh, J Frank Nash, Heidi Bialk, Peter Styczynski, John Troutman, Andrea Edginton.  Mechanistic Skin Modeling of Plasma Concentrations of Sunscreen Active Ingredients Following Facial Application. Journal of Pharmaceutical Sciences 113 (3), 806-825
  
  

• Abdullah Hamadeh, Abdulkarim Najjar, John Troutman, Andrea Edginton.  Enhancement of Skin Permeability Prediction through PBPK Modeling, Bayesian Inference, and Experiment Design.  Pharmaceutics 15 (12), 2667.

Epidemiology and pharmacoeconomics

• Farinaz Forouzannia, Abdullah Hamadeh, Ana Maria Passos‐Castilho, Aysegul Erman, Amanda Yu, Zeny Feng, Naveed Z Janjua, Beate Sander, Christina Greenaway, William WL Wong.  Impact of new direct‐acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver International 44 (6), 1383-1395.
  
  

• Abdullah Hamadeh, Zeny Feng, Jessmyn Niergarth, William WL Wong.  Estimation of COVID-19 period prevalence and the undiagnosed population in Canadian provinces: Model-based analysis.  JMIR Public Health and Surveillance 7 (9), e26409.
  
  

• Abdullah Hamadeh, Alex Haines, Zeny Feng, Hla Hla Thein, Naveed Janjua, Murray Krahn, William WL Wong.  Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population‐based cohort studies.  Journal of Viral Hepatitis 27 (12), 1419-1429.
  
  

• Abdullah Hamadeh, Zeny Feng, Murray Krahn, William WL Wong.  A model-based framework for chronic hepatitis C prevalence estimation.  PLoS one 14 (11), e0225366.